Bomedemstat in Patients With Polycythemia Vera

• Status: Not yet recruiting
• Trial end date: 2024-07-01

Summary

This is a Phase 2 open label study of an orally administered LSD1 inhibitor, bomedemstat (IMG-7289), in patients with polycythemia vera.

This study investigates the following:

• The safety and tolerability of bomedemstat

• The pharmacodynamic effect of bomedemstat

• Phase: Phase 2

Details

• Lead Sponsor: Imago BioSciences,Inc.